| Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ... JAMA oncology 4 (12), 1721-1728, 2018 | 2149 | 2018 |
| Fulminant myocarditis with combination immune checkpoint blockade DB Johnson, JM Balko, ML Compton, S Chalkias, J Gorham, Y Xu, ... New England Journal of Medicine 375 (18), 1749-1755, 2016 | 2109 | 2016 |
| 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology … AR Lyon, T Lopez-Fernandez, LS Couch, R Asteggiano, MC Aznar, ... European Heart Journal-Cardiovascular Imaging 23 (10), e333-e465, 2022 | 1557 | 2022 |
| Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging AP Gomes, NL Price, AJY Ling, JJ Moslehi, MK Montgomery, L Rajman, ... Cell 155 (7), 1624-1638, 2013 | 1479 | 2013 |
| Telomere dysfunction induces metabolic and mitochondrial compromise E Sahin, S Colla, M Liesa, J Moslehi, FL Müller, M Guo, M Cooper, ... Nature 470 (7334), 359-365, 2011 | 1413 | 2011 |
| Myocarditis in patients treated with immune checkpoint inhibitors SS Mahmood, MG Fradley, JV Cohen, A Nohria, KL Reynolds, ... Journal of the American College of Cardiology 71 (16), 1755-1764, 2018 | 1318 | 2018 |
| Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline SH Armenian, C Lacchetti, A Barac, J Carver, LS Constine, N Denduluri, ... Journal of Clinical Oncology 35 (8), 893-911, 2017 | 1309 | 2017 |
| Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study JE Salem, A Manouchehri, M Moey, B Lebrun-Vignes, L Bastarache, ... The Lancet Oncology 19 (12), 1579-1589, 2018 | 941 | 2018 |
| Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations G Curigliano, D Lenihan, M Fradley, S Ganatra, A Barac, A Blaes, ... Annals of Oncology 31 (2), 171-190, 2020 | 865 | 2020 |
| Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis JJ Moslehi, JE Salem, JA Sosman, B Lebrun-Vignes, DB Johnson The Lancet 391 (10124), 933, 2018 | 805 | 2018 |
| Cardiovascular toxic effects of targeted cancer therapies JJ Moslehi New England Journal of Medicine 375 (15), 1457-1467, 2016 | 605 | 2016 |
| Immune-checkpoint inhibitors: long-term implications of toxicity DB Johnson, CA Nebhan, JJ Moslehi, JM Balko Nature Reviews Clinical Oncology 19 (4), 254-267, 2022 | 596 | 2022 |
| Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the C … AR Lyon, S Dent, S Stanway, H Earl, C Brezden‐Masley, A Cohen‐Solal, ... European journal of heart failure 22 (11), 1945-1960, 2020 | 581 | 2020 |
| Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document E Ammirati, M Frigerio, ED Adler, C Basso, DH Birnie, M Brambatti, ... Circulation: Heart Failure 13 (11), e007405, 2020 | 573 | 2020 |
| Immune checkpoint inhibitors and cardiovascular toxicity AR Lyon, N Yousaf, NML Battisti, J Moslehi, J Larkin The Lancet Oncology 19 (9), e447-e458, 2018 | 502 | 2018 |
| Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association RD Kociol, LT Cooper, JC Fang, JJ Moslehi, PS Pang, MA Sabe, RV Shah, ... Circulation 141 (6), e69-e92, 2020 | 499 | 2020 |
| Tyrosine kinase inhibitor–associated cardiovascular toxicity in chronic myeloid leukemia JJ Moslehi, M Deininger Journal of clinical oncology 33 (35), 4210-4218, 2015 | 478 | 2015 |
| Cardiovascular toxicities associated with immune checkpoint inhibitors JR Hu, R Florido, EJ Lipson, J Naidoo, R Ardehali, CG Tocchetti, AR Lyon, ... Cardiovascular research 115 (5), 854-868, 2019 | 417 | 2019 |
| High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells A Sharma, PW Burridge, WL McKeithan, R Serrano, P Shukla, N Sayed, ... Science translational medicine 9 (377), eaaf2584, 2017 | 370 | 2017 |
| Abatacept for severe immune checkpoint inhibitor–associated myocarditis JE Salem, Y Allenbach, A Vozy, N Brechot, DB Johnson, JJ Moslehi, ... New England Journal of Medicine 380 (24), 2377-2379, 2019 | 369 | 2019 |
Joe-elie SalemAPHP確認したメール アドレス: aphp.fr
